Cytomegalovirus infections in solid organ transplantation: A review

Infection and Chemotherapy

Volumn 45, Issue 3, 2013, Pages 260-271

  Ramanan, Poornima ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytomegalovirus; Diagnosis; Prevention; Transplant; Treatment

Indexed keywords

ANTIVIRUS AGENT; ARTESUNATE; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOPROPAVIR; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GAMMA INTERFERON; GANCICLOVIR; GLYCOPROTEIN B; IMMUNOGLOBULIN G ANTIBODY; LEFLUNOMIDE; LETERMOVIR; MIFAMURTIDE; NUCLEIC ACID; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

ALLOGRAFT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BONE MARROW SUPPRESSION; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DNA POLYMORPHISM; DRUG BIOAVAILABILITY; GRAFT RECIPIENT; GRAFT REJECTION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY DIAGNOSIS; LEUKOPENIA; LUNG TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; REVIEW; SEROLOGY; SEROPREVALENCE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA; VIRUS CULTURE; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 84887560446     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2013.45.3.260     Document Type: Review

References (87)

1. Fishman JA. Overview: cytomegalovirus and the herpesviruses in transplantation. Am J Transplant 2013;13 (Suppl 3):1-8; quiz 8.
2. Craig JM, Macauley JC, Weller TH, and Wirth P. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med 1957;94:4-12.
3. Smith MG. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 1956;92:424-30.
4. Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest 2011;121:1673-80.
5. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010;20:202-13.
6. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis 2010;50:1439-47.
7. Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 2013;85:893-8.
8. Mendez-Eirin E, Paniagua-Martín MJ, Marzoa-Rivas R, Barge-Caballero E, Grille-Cancela Z, Cañizares A, Naya-Leira C, Gargallo-Fernández P, Castro-Beiras A, Crespo-Leiro M. Cumulative incidence of cytomegalovirus infection and disease after heart transplantation in the last decade: effect of preemptive therapy. Transplant Proc 2012;44:2660-2.
9. Hammond SP, Martin ST, Roberts K, Gabardi s, Fuhlbrigge AL, Camp PC, Goldberg HJ, Marty FM, Baden LR. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. Transplinfect Dis 2013;15:163-70.
10. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010;70:965-81.
11. Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6.
12. Razonable RR. Strategies for managing cytomegalovirus in transplant recipients. Expert Opin Pharmacother 2010;11:1983-97.
13. Gordon CR, Avery RK, Abouhassan W, Siemionow M. Cytomegalovirus and other infectious issues related to face transplantation: specific considerations, lessons learned, and future recommendations. Plast Reconstr Surg 2011;127:1515-23.
14. Razonable RR, Humar A; AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013;13 (Suppl 4):93-106.
15. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14.
16. Luan FL. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction. Transplant Proc 2013;45:175-7.
17. Requião-Moura LR, Ferraz E, Matos AC, Tonato EJ, Ozaki KS, Durão MS, Câmara NO, Pacheco-Silva A. Comparison of long-term effect of thymoglobulin treatment in patients with a high risk of delayed graft function. Transplant Proc 2012;44:2428-33.
18. Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001;184:1461-4.
19. Brennan DC, Legendre C, Patel D, Mange K, Wiland A, McCague K, Shihab FS. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials. Am J Transplant 2011;11:2453-62.
20. Humar A, Asberg A, Kumar D, Hartmann A, Moussa G, Jardine A, Rollag H, Mouas H, Gahlemann CG, Pescovitz MD; VICTOR study group. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 2009;9:374-81.
21. Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007;83:359-62.
22. Kwakkel-van Erp JM, Paantjens AW, van Kessel DA, Grutters JC, van den Bosch JM, van de GraafEA, Otten HG. Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survivalin lung transplantation. Clin Exp Immunol 2011;165:410-6.
23. Krishnan A, Zhou W, Lacey SF, Limaye AP, Diamond DJ, La Rosa C. Programmed death-1 receptor and interleukin-10 in liver transplant recipients at high risk for late cytomegalovirus disease. Transplinfect Dis 2010;12:363-70.
24. Cummins NW, Deziel PJ, Abraham RS, Razonable RR. Deficiency of cytomegalovirus (CMV)-specific CD8+ T cells in patients presenting with late-onset CMV disease several years after transplantation. Transplinfect Dis 2009;11:20-7.
25. Weseslindtner L, Kerschner H, Steinacher D, Nachbagauer R, Kundi M, Jaksch P, Simon B, Hatos-Agyi L, Scheed A, Klepetko W, Puchhammer-Stöckl E. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am J Transplant 2012;12:2172-80.
26. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008;14:4849-60.
27. La Rosa C, Diamond DJ. The immune response to human CMV. Future Virol 2012;7:279-93.
28. Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007;44:1315-20.
29. Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012;205:639-46.
30. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. Humar A American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006;6:262-74.
31. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004;4:611-20.
32. Freeman RB Jr. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009;9:2453-8.
33. Kotton CN. CMV: Prevention, Diagnosis and Therapy. Am J Transplant 2013;13 (Suppl 3):24-40; quiz 40.
34. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996;23:468-74.
35. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997;103:106-13.
36. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, Araya VR, Dodson F, Fung JJ, Rakela J, Vargas HE. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003;76:1487-91.
37. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CG, Paya CV. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995;20:1346-53.
38. Madalosso C, De Souza NF Jr, Ilstrup DM, Wiesner RH, Krom RA. Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 1998;66:294-7.
39. Sagedal S, Nordal KP, Hartmann A, Sund S, Scott H, Degré M, Foss A, Leivestad T, Osnes K, Fauchald P, Rollag H. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002;2:850-6.
40. Streblow DN, Orloff SL, Nelson JA. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 2007;19:577-82.
41. Potena L and Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007;20:425-31.
42. Thomas LD, Milstone AP, Miller GG, Loyd JE, Stephen Dummer J. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen. Clin Transplant 2009;23:476-83.
43. Leung Ki EL, Venetz JP, Meylan P, Lamoth F, Ruiz J, Pascual M. Cytomegalovirus infection and new-onset post-transplant diabetes mellitus. Clin Transplant 2008;22:245-9.
44. Hayden RT, Yan X, Wick MT, Rodriguez AB, Xiong X, Ginocchio CC, Mitchell MJ, Caliendo AM; College of American Pathologists Microbiology Resource Committee. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J Clin Microbiol 2012;50:337-45.
45. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin Infect Dis 2012;54:1793-7.
46. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK; American Society of Transplantation Infectious Diseases Community of Practice; Canadian Society of Transplantation. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009;9:258-68.
47. Lisboa LF, Asberg A, Kumar D, Pang X, Hartmann A, Preiksaitis JK, Pescovitz MD, Rollag H, Jardine AG, Humar A. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011;91:231-6.
48. Hirsch HH, Lautenschlager I, Pinsky BA, Cardeñoso L, Aslam S, Cobb B, Vilchez RA, Valsamakis A. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013;56:367-73.
49. Razonable RR, Åsberg A, Rollag H, Duncan J, Boisvert D, Yao JD, Caliendo AM, Humar A, Do TD. Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the world health organization international standard is predictive of CMV disease resolution in transplant recipients. Clin Infect Dis 2013;56:1546-53.
50. Humar A, Mazzulli T, Moussa G, Razonable RR, Paya CV, Pescovitz MD, Covington E, Alecock E; Valganciclovir Solid Organ Transplant Study Group. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/ R- transplant recipients. Am J Transplant 2005;5:1065-70.
51. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002;40:746-52.
52. Lisboa LF, Kumar D, Wilson LE, Humar A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012;93:195-200.
53. Manuel O, Husain S, Kumar D, Zayas C, Mawhorter S, Levi ME, Kalpoe J, Lisboa L, Ely L, Kaul DR, Schwartz BS, Morris MI, Ison MG, Yen-Lieberman B, Sebastian A, Assi M, Humar A. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clini Infect Dis 2013;56:817-24.
54. Kumar D, Chernenko S, Moussa G, Cobos I, Manuel O, Preiksaitis J, Venkataraman S, Humar A. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009;9:1214-22.
55. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin Infect Dis 2012;55:1678-89.
56. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228-37.
57. Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, Dunitz J, Milstone A, Reynolds J, Yung GL, Chan KM, Aris R, Garrity E, Valentine V, McCall J, Chow SC, Davis RD, Avery R. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010;152:761-9.
58. Finlen Copeland CA, Davis WA, Snyder LD, Banks M, Avery R, Davis RD, Palmer SM. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant 2011;30:990-6.
59. Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010; 90:672-6.
60. Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transplinfect Dis 2012;14:248-58.
61. Weill D, Lock BJ, Wewers DL, Young KR, Zorn GL, Early L, Kirklin JK, McGiffin DC. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction. Am J Transplant 2003;3:492-6.
62. Bonaros N, Mayer B, Schachner T, Laufer G, Kocher A. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Clin Transplant 2008;22:89-97.
63. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A; Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in sol id organ transplantation. Transplantation 2010;89:779-95.
64. Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients. J Infect Dis 2010;202:585-94.
65. Kalil AC, Levitsky J, Lyden E, Stoner J, Freifeld AG. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-80.
66. Martín-Gandul C, Pérez-Romero P, Sánchez M, Bernal G, Suárez G, Sobrino M, Merino L, Cisneros JM, Cordero E; Spanish Network for Research in Infectious Diseases. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol 2013;56:13-8.
67. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Syst Rev 2013;2:CD005133.
68. Kliem V, Fricke L, Wollbrink T, Burg M, Radermacher J, Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008;8:975-83.
69. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002;185:20-7.
70. Eid AJ, Arthurs SK, Deziel PJ, Wilhelm MP, Razonable RR. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22:162-70.
71. Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011;92:217-23.
72. Couzi L, Helou S, Bachelet T, Moreau K, Martin S, Morel D, Lafon ME, Boyer B, Alain S, Garrigue I, Merville P. High incidence of anticytomegalovirus drug resistance among D+R- kidney transplant recipients receiving preemptive therapy. Am J Transplant 2012;12:202-9.
73. Boivin G, Goyette N, Farhan M, Ives J, Elston R. Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis. J Clin Virol 2012;53:208-13.
74. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomi sed placebo-controlled trial. Lancet 2011;377:1256-63.
75. Lisboa LF, Preiksaitis JK, Humar A, Kumar D. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation 2011;92:1063-8.
76. Dunn DL, Mayoral JL, Gillingham KJ, Loeffler CM, Brayman KL, Kramer MA, Erice A, Balfour HH Jr, Fletcher CV, Bolman RM 3rd, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991;51:98-106.
77. Keay S, Petersen E, Icenogle T, Zeluff BJ, Samo T, Busch D, Newman CL, Buhles WC Jr, Merigan TC. Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev Infect Dis 1988;10 (Suppl 3):S563-72.
78. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A; VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007;7:2106-13.
79. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002;186:829-33.
80. Sia IG, Wilson JA, Groettum CM, Espy MJ, Smith TF, Paya CV. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000;181:717-20.
81. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007;45:439-47.
82. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010;23:689-712.
83. Le Page AK, Jager MM, Iwasenko JM, Scott GM, Alain S, Rawlinson WD. Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients. Clin Infect Dis 2013;56:1018-29.
84. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000;356:645-9.
85. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000;97:8039-44.
86. Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009;14:697-704.
87. Sabé N, González-Costello J, Rama I, Niubó J, Bodro M, Roca J, Cruzado JM, Manito N, Carratalà J. Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors. Transplint 2012;25:e78-82.